These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21233424)

  • 1. Health advocacy organizations and the pharmaceutical industry: an analysis of disclosure practices.
    Rothman SM; Raveis VH; Friedman A; Rothman DJ
    Am J Public Health; 2011 Apr; 101(4):602-9. PubMed ID: 21233424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and Disclosure of Potential Conflicts of Interest in Dermatology Patient Advocacy Organizations.
    Li DG; Singer S; Mostaghimi A
    JAMA Dermatol; 2019 Apr; 155(4):460-464. PubMed ID: 30698625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical Industry Support of US Patient Advocacy Organizations: An International Context.
    Kang SY; Bai G; Karas L; Anderson GF
    Am J Public Health; 2019 Apr; 109(4):559-561. PubMed ID: 30789768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Content Analysis of Patient Advocacy Organization Policies Addressing Institutional Conflicts of Interest.
    Brems JH; McCoy MS
    AJOB Empir Bioeth; 2019; 10(4):215-221. PubMed ID: 31593523
    [No Abstract]   [Full Text] [Related]  

  • 5. Patient advocacy organizations and corporate relationships.
    Weinberg M
    Am J Public Health; 2011 Apr; 101(4):582-3; author reply 583. PubMed ID: 21389285
    [No Abstract]   [Full Text] [Related]  

  • 6. In whose interest? Relationships between health consumer groups and the pharmaceutical industry in the UK.
    Jones K
    Sociol Health Illn; 2008 Sep; 30(6):929-43. PubMed ID: 18761512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient Advocacy Organizations, Industry Funding, and Conflicts of Interest.
    Rose SL; Highland J; Karafa MT; Joffe S
    JAMA Intern Med; 2017 Mar; 177(3):344-350. PubMed ID: 28114624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK.
    Rickard E; Ozieranski P; Mulinari S
    Health Policy; 2019 Dec; 123(12):1244-1250. PubMed ID: 31455562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Industry funding of patient and health consumer organisations: systematic review with meta-analysis.
    Fabbri A; Parker L; Colombo C; Mosconi P; Barbara G; Frattaruolo MP; Lau E; Kroeger CM; Lunny C; Salzwedel DM; Mintzes B
    BMJ; 2020 Jan; 368():l6925. PubMed ID: 31969320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing good scientific publishing practices: one pharmaceutical company's perspective.
    Dowsett SA; Van Campen LE; Bednar LA
    Curr Med Res Opin; 2010 Jun; 26(6):1249-54. PubMed ID: 20350148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient advocacy organizations: institutional conflicts of interest, trust, and trustworthiness.
    Rose SL
    J Law Med Ethics; 2013; 41(3):680-7. PubMed ID: 24088159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Research funding, conflicts of interest, and the meta-methodology of public relations.
    Rampton S; Stauber J
    Public Health Rep; 2002; 117(4):331-9. PubMed ID: 12477914
    [No Abstract]   [Full Text] [Related]  

  • 13. Reporting of financial conflicts of interest in clinical practice guidelines: a case study analysis of guidelines from the Canadian Medical Association Infobase.
    Shnier A; Lexchin J; Romero M; Brown K
    BMC Health Serv Res; 2016 Aug; 16(a):383. PubMed ID: 27528247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical communication companies and industry grants.
    Rothman SM; Brudney KF; Adair W; Rothman DJ
    JAMA; 2013 Dec; 310(23):2554-8. PubMed ID: 24346991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating solutions to sponsorship bias.
    Doucet M; Sismondo S
    J Med Ethics; 2008 Aug; 34(8):627-30. PubMed ID: 18667655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond Disclosure: Developing Law and Policy to Tackle Corporate Influence.
    Marks JH
    Am J Law Med; 2020 May; 46(2-3):275-296. PubMed ID: 32659196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest.
    Rothman DJ; McDonald WJ; Berkowitz CD; Chimonas SC; DeAngelis CD; Hale RW; Nissen SE; Osborn JE; Scully JH; Thomson GE; Wofsy D
    JAMA; 2009 Apr; 301(13):1367-72. PubMed ID: 19336712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guidelines for interactions between clinical faculty and the pharmaceutical industry: one medical school's approach.
    Coleman DL; Kazdin AE; Miller LA; Morrow JS; Udelsman R
    Acad Med; 2006 Feb; 81(2):154-60. PubMed ID: 16436576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How do health consumer organisations in Australia manage pharmaceutical industry sponsorship? A cross-sectional study.
    Lau E; Fabbri A; Mintzes B
    Aust Health Rev; 2019 Aug; 43(4):474-480. PubMed ID: 30021681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Transparency in relations between multinational R&D pharmaceutical companies' corporate social responsibility activities and patient organizations in the Europe, Japan, and the United States].
    Kato M; Ishikawa H; Okuhara T; Kiuchi T
    Nihon Koshu Eisei Zasshi; 2019; 66(12):746-755. PubMed ID: 31875625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.